SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau Medical announced that a pooled analysis of safety and…

Alpha Tau Medical Ltd. · 6-K filed Apr 27, 2026 at 09:00 ET

At the news

BULLISHIMPACT 7/10

6-K filed Apr 27, 2026 at 09:00 ET

Alpha Tau Medical announced that a pooled analysis of safety and efficacy data from 58 patients across three clinical studies of its Alpha DaRT therapy for advanced pancreatic cancer has been accepted for presentation at the 2026 ASCO Annual Meeting, a premier oncology conference. This represents a significant scientific validation of its clinical program and builds momentum for its ongoing IMPACT and ACAPELLA trials in the U.S. and France.

  • Abstract titled 'Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer' accepted for presentation at the 2026 ASCO Annual Meeting.
  • Pooled data includes 58 patients from three prospective clinical studies conducted in Canada and Israel.
  • ASCO is the world's largest and most prestigious oncology conference; abstract acceptance is peer-reviewed and highly competitive.
  • Alpha Tau highlighted this as a major milestone, validating the maturity and strength of its pancreatic cancer clinical evidence base.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access